We are focused on therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. Biologic drug concentrations vary widely between patients, leading to unnecessary side effects and suboptimal clinical outcomes. By tracking drug levels in individual patients, these high cost treatments can be personalized to improve treatment results and unlock savings for healthcare systems. Aegirbio is setting new standards in this field by pioneering Point of Care and Point of Need tests that can provide results within minutes.
A highly accurate test for detecting the COVID-19 virus using saliva. Simplified, qualitative, point-of-care test with results in 5-10 minutes. Avoids the complications of nasal swabs, blood draws, and delayed results.
Ensuring continuity of care for patients living with Multiple Sclerosis (MS) during the COVID-19 pandemic is critical for providers and patients.
moNATor measures the amount of Tysabri in an MS patient’s blood. This information may help optimize treatment intervals, reducing the risk of exposure to COVID-19 and also potentially reducing the risk of PML